Integrated reporting of suspected adverse drug reactions (ADRs) to the Yellow Card Scheme has now been rolled out to EMIS Web users in England. The Medicines and Healthcare products Regulatory Agency (MHRA)’s Yellow Card Scheme reports act as an early warning of previously unrecognised ADRs as well as providing valuable information on already recognised ADRs, helping to ensure that medicines are acceptably safe.
Integrated Yellow Card reporting is a secure and fast method for healthcare professionals to report suspected ADRs through a few simple steps. Much of the information needed is populated automatically from the patient and reporter record. This mean that clinicians only need to complete a few additional pieces of information. A copy of the report is held on the patient’s record.
MHRA’s vigilance and risk management of medicines’ head of pharmacovigilance strategy, Mick Foy, said: “This is an important milestone for the Yellow Card Scheme.
“All Yellow Card reports can be a source of potential new safety information. Expanding the availability of easy-to-use routes of reporting is invaluable towards increased reporting and protecting patient safety.”
Dr Shaun O’ Hanlon, EMIS Group chief medical officer, said: “Clinical safety is EMIS Group’s number one priority. Integrating Yellow Card reporting into EMIS Web is another way that clinicians that use our systems can contribute to preventative healthcare, enabling the MHRA to gather information to continue their work to improve medication safety.”
EMIS Web users in England can find more information on EMISNow.